Bezuclastinib free base · Synonyms: CGT-9486 | PLX 9486

Bezuclastinib is a potent inhibitor of c-kit.

For research use only. Not for human or veterinary use.

Target c-Kit

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

Bezuclastinib structure

CAS No.: 1616385-51-3

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
500 mg	USD 485.00	BP-01906-500mg	In stock	Get quote
1 g	USD 830.00	BP-01906-1g	In stock	Get quote
5 g	Inquire	BP-01906-5g	Inquire	Inquire

Need another size or custom synthesis? Request a quote.

Description

Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001<IC50<1 μM; extracted from patent WO2014100620 A2, compound P-2007). Bezuclastinib is a tyrosine kinase inhibitor.

Biological activity

In Vivo Bezuclastinib (25 mg/kg, p.o., 3 days) shows a brain:plasma ratio of 0.07 in rats.

Identifiers

SMILES: O=C(C1=NNC(C)=C1C)NC2=CN=C3NC(C4=CC=CC=C4)=CC3=C2
InChIKey: NVSHVYGIYPBTEZ-UHFFFAOYSA-N

Specifications

MW (average): 331.3712
Formula: C₁₉H₁₇N₅O
CAS No.: 1616385-51-3
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4°C, sealed storage, away from moisture and light; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO 80 mg/mL

Documents

References

[1]. Guoxian Wu, et al. Preparation of phenylpyrrolopyridinylheteroarylcarboxamide derivatives and analogs for use as c-kit protein kinases or mutant c-kit protein kinases modulators. Patent WO2014100620 A2.

[2]. WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.

Same target

Search c-Kit

Same research area

Search Cancer